# Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD

> **NCT03461276** · PHASE2 · COMPLETED · sponsor: **Araclon Biotech S.L.** · enrollment: 134 (actual)

## Conditions studied

- Mild Cognitive Impairment
- Alzheimer Disease

## Interventions

- **BIOLOGICAL:** ABvac40
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03461276
- **Lead sponsor:** Araclon Biotech S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-13
- **Primary completion:** 2023-03-23
- **Final completion:** 2023-03-23
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03461276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03461276, "Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03461276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*